APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Drugs for the Treatment of Wet AMD

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Anti-VEGF Drugs for the Treatment of Wet AMD Industry Growth and Trends Forecast to 2032

27 December 202593 pages

Choose your research edition.

Industry ResearchAnti-VEGF Drugs for the Treatment of Wet AMD Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-VEGF Drugs for the Treatment of Wet AMD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD include Chengdu Kanghong Pharmaceutica, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Anti-VEGF Drugs for the Treatment of Wet AMD market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anti-VEGF Drugs for the Treatment of Wet AMD market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-VEGF Drugs for the Treatment of Wet AMD market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-VEGF Drugs for the Treatment of Wet AMD.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Anti-VEGF Drugs for the Treatment of Wet AMD market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anti-VEGF Drugs for the Treatment of Wet AMD Market by Company

Chengdu Kanghong Pharmaceutica

Samsung Bioepis

Roche

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Type

Single target Drugs

Multi-target Drugs

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Drugs for the Treatment of Wet AMD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Drugs for the Treatment of Wet AMD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-VEGF Drugs for the Treatment of Wet AMD manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Anti-VEGF Drugs for the Treatment of Wet AMD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Single target Drugs Table 2. Major Company of Multi-target Drugs Table 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 5. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type (2021-2026) Table 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (US$ Million) Table 7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type (2021-2026) Table 8. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2026) & (US$/Unit) Table 9. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 10. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type (2027-2032) Table 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (US$ Million) Table 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type (2027-2032) Table 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2027-2032) & (US$/Unit) Table 14. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 15. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 17. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 21. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (US$ Million) Table 24. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends Table 25. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers Table 26. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges Table 27. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints Table 28. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Company (2021-2026) Table 30. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Company (2021-2026) & (K Units) Table 31. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Company (2021-2026) Table 32. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Anti-VEGF Drugs for the Treatment of Wet AMD Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Anti-VEGF Drugs for the Treatment of Wet AMD Major Company Production Sites and Headquarters Table 35. Global Anti-VEGF Drugs for the Treatment of Wet AMD Company, Product Type & Application Table 36. Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Anti-VEGF Drugs for the Treatment of Wet AMD by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026) & (K Units) Table 41. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Region (2021-2026) Table 42. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026) & (US$ Million) Table 43. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Region (2021-2026) Table 44. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2027-2032) & (K Units) Table 46. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Region (2027-2032) Table 47. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2027-2032) & (US$ Million) Table 48. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Region (2027-2032) Table 49. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 52. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application (2021-2026) Table 53. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (US$ Million) Table 54. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application (2021-2026) Table 55. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2026) & (US$/Unit) Table 56. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 57. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application (2027-2032) Table 58. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (US$ Million) Table 59. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application (2027-2032) Table 60. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2027-2032) & (US$/Unit) Table 61. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 62. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 64. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 68. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (US$ Million) Table 71. Chengdu Kanghong Pharmaceutica Company Information Table 72. Chengdu Kanghong Pharmaceutica Business Overview Table 73. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 75. Chengdu Kanghong Pharmaceutica Recent Development Table 76. Samsung Bioepis Company Information Table 77. Samsung Bioepis Business Overview Table 78. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 80. Samsung Bioepis Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 85. Roche Recent Development Table 86. Regeneron Pharmaceuticals Company Information Table 87. Regeneron Pharmaceuticals Business Overview Table 88. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 90. Regeneron Pharmaceuticals Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 95. Novartis Recent Development Table 96. Coherus BioSciences Company Information Table 97. Coherus BioSciences Business Overview Table 98. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 100. Coherus BioSciences Recent Development Table 101. Biocon Biologics Company Information Table 102. Biocon Biologics Business Overview Table 103. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 105. Biocon Biologics Recent Development Table 106. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 107. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 108. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2026) Table 109. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032) & (K Units) Table 110. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share Forecast by Country (2027-2032) Table 111. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026) & (US$ Million) Table 113. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country (2021-2026) Table 114. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Share Forecast by Country (2027-2032) Table 116. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 118. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2026) Table 119. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032) & (K Units) Table 120. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share Forecast by Country (2027-2032) Table 121. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026) & (US$ Million) Table 123. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country (2021-2026) Table 124. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 128. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2026) Table 129. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032) & (K Units) Table 130. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026) & (US$ Million) Table 133. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country (2021-2026) Table 134. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Share Forecast by Country (2027-2032) Table 136. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 138. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2026) Table 139. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032) & (K Units) Table 140. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share Forecast by Country (2027-2032) Table 141. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026) & (US$ Million) Table 143. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country (2021-2026) Table 144. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 148. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2026) Table 149. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032) & (K Units) Table 150. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026) & (US$ Million) Table 153. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country (2021-2026) Table 154. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Share Forecast by Country (2027-2032) Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Anti-VEGF Drugs for the Treatment of Wet AMD Distributors List Table 159. Anti-VEGF Drugs for the Treatment of Wet AMD Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Anti-VEGF Drugs for the Treatment of Wet AMD Image Figure 2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (2021-2032) & (K Units) Figure 5. Single target Drugs Image Figure 6. Global Single target Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Multi-target Drugs Image Figure 8. Global Multi-target Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Type 2025 VS 2032 Figure 11. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type in 2025 Figure 12. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type in 2025 Figure 13. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type in 2025 Figure 14. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type in 2025 Figure 17. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Anti-VEGF Drugs for the Treatment of Wet AMD Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 25. Retail Pharmacies Image Figure 26. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Application 2025 VS 2032 Figure 31. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application in 2025 Figure 32. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application in 2025 Figure 33. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application in 2025 Figure 34. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application in 2025 Figure 37. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share in Value by Application in 2025 Figure 41. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Single target Drugs
  • Multi-target Drugs
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chengdu Kanghong Pharmaceutica
  • Samsung Bioepis
  • Roche
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Type
  6. 1.3.1 Single target Drugs
  7. 1.3.2 Multi-target Drugs
  8. 1.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type
  9. 1.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends
  2. 2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers
  3. 2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2026)
  2. 3.2 Global Top Players by Anti-VEGF Drugs for the Treatment of Wet AMD Sales (2021-2026)
  3. 3.3 Global Top Players by Anti-VEGF Drugs for the Treatment of Wet AMD Price (2021-2026)
  4. 3.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Major Company Production Sites & Headquarters
  6. 3.6 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company, Product Type & Application
  7. 3.7 Global Anti-VEGF Drugs for the Treatment of Wet AMD Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-VEGF Drugs for the Treatment of Wet AMD Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-VEGF Drugs for the Treatment of Wet AMD Tier 1, Tier 2, and Tier 3
4 Anti-VEGF Drugs for the Treatment of Wet AMD Regional Status and Outlook
  1. 4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Historic Market Size by Region
  3. 4.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Forecasted Market Size by Region
  7. 4.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anti-VEGF Drugs for the Treatment of Wet AMD by Application
  1. 5.1 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application
  6. 5.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chengdu Kanghong Pharmaceutica
  2. 6.1.1 Chengdu Kanghong Pharmaceutica Company Information
  3. 6.1.2 Chengdu Kanghong Pharmaceutica Business Overview
  4. 6.1.3 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  6. 6.1.5 Chengdu Kanghong Pharmaceutica Recent Developments
  7. 6.2 Samsung Bioepis
  8. 6.2.1 Samsung Bioepis Company Information
  9. 6.2.2 Samsung Bioepis Business Overview
  10. 6.2.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  12. 6.2.5 Samsung Bioepis Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  18. 6.3.5 Roche Recent Developments
  19. 6.4 Regeneron Pharmaceuticals
  20. 6.4.1 Regeneron Pharmaceuticals Company Information
  21. 6.4.2 Regeneron Pharmaceuticals Business Overview
  22. 6.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  24. 6.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Coherus BioSciences
  32. 6.6.1 Coherus BioSciences Company Information
  33. 6.6.2 Coherus BioSciences Business Overview
  34. 6.6.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  36. 6.6.5 Coherus BioSciences Recent Developments
  37. 6.7 Biocon Biologics
  38. 6.7.1 Biocon Biologics Company Information
  39. 6.7.2 Biocon Biologics Business Overview
  40. 6.7.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  42. 6.7.5 Biocon Biologics Recent Developments
7 North America by Country
  1. 7.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country
  2. 7.1.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026)
  4. 7.1.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032)
  5. 7.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  6. 7.2.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026)
  8. 7.2.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country
  2. 8.1.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026)
  4. 8.1.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  6. 8.2.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026)
  8. 8.2.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country
  2. 9.1.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  6. 9.2.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country
  2. 10.1.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026)
  4. 10.1.3 South America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032)
  5. 10.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  6. 10.2.1 South America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026)
  8. 10.2.3 South America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country
  2. 11.1.1 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  6. 11.2.1 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Analysis
  2. 12.1.1 Anti-VEGF Drugs for the Treatment of Wet AMD Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process
  7. 12.2 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Distributors
  10. 12.2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst